Skip to main content

Advertisement

SpringerLink
Log in

Is the promise of randomized control trials ("evidence-based medicine") overstated?

  • Invited Commentary
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Cook DJ, Guyatt GH, Laupacis A, Sackett DL: Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992, 102(suppl 4):305S-311S.

    PubMed  CAS  Google Scholar 

  2. Biller J, Feinberg WM, Castaldo JE, et al.: Guidelines for carotid endarterectomy. A statement of healthcare professionals from a special writing group of the Stroke Council, American Heart Association and the American Academy of Neurology. Stroke 1998, 29:554–562.

    PubMed  CAS  Google Scholar 

  3. Meinert CL: Clinical Trials: Design, Conduct, and Analysis. New York: Oxford University Press; 1986.

    Google Scholar 

  4. Sze P, Reitman D, Pincus M, Sacks HS, Chalmers TC: Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized control trials. Stroke 1988, 19:436–442.

    PubMed  CAS  Google Scholar 

  5. Davidoff F, DeAngelis CD, Drazen JM, et al.: Sponsorship, authorship, and accountability. N Engl J Med 2001, 345:825–827.

    Article  PubMed  CAS  Google Scholar 

  6. EC/IC Bypass Study Group: Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N Engl J Med 1985, 313:191–200.

    Google Scholar 

  7. Fields WS, LeMak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8:301–316.

    PubMed  CAS  Google Scholar 

  8. The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978, 299:53–59.

    Article  Google Scholar 

  9. The American-Canadian Cooperative Study Group: Persantineaspirin trial in cerebral ischemia. Part ll. Endpoint results. Stroke 1985, 16:406–415.

    Google Scholar 

  10. Bousser MG, Schwege E, Haguenau M, et al.: "A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983, l4:5–14.

    Google Scholar 

  11. European Stroke Prevention Study Group: ESPS: principal end points. Lancet 1987, 2:1351–1354.

    Google Scholar 

  12. Britton M, Helmers C, Samuelsson K: High dose acetylsalicylic acid after cerebral infarction: a Swedish co-operative study. Stroke 1987, l8:325–334.

    Google Scholar 

  13. UK-TIA Study Group: The United Kingdom transient ischaemic attack (lUK-TlA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044–1054.

    Google Scholar 

  14. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261–1266.

    Article  Google Scholar 

  15. The SALT Collaborative Group: Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991, 338:1345–1349.

    Article  Google Scholar 

  16. Antiplatelet Trialists’ Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988, 296:320–331.

    Google Scholar 

  17. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomized trials of antiplatelet treatment. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81–106.

    Google Scholar 

  18. Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G: A randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 1982, l3:175–179.

    Google Scholar 

  19. Matias-Guiu J, Davalos A, Pico M, et al.: Low dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Act Neurol Scand 1987, 76:413–421.

    Article  CAS  Google Scholar 

  20. Gent M, Blakely JA, Easton JD, et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989, l:1215–1220.

    Article  Google Scholar 

  21. Hass WK, Easton JD, Adams HP Jr, et al.: A randomized trial comparing ticlcopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989, 321:501–507.

    Article  PubMed  CAS  Google Scholar 

  22. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329–1339.

    Article  Google Scholar 

  23. Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1–13.

    Article  PubMed  CAS  Google Scholar 

  24. Sivenius J, Puranen J: Antiplatelet therapy in secondary prevention of stroke. A review of efficacy and tolerability. CNS Drugs 1997, 8:38–50.

    CAS  Google Scholar 

  25. Caplan LR: Are terms such as completed stroke, or RIND of continued usefulness? Stroke 1983, 14:431–433.

    PubMed  CAS  Google Scholar 

  26. Caplan LR: TIAs—we need to return to the question, "What is wrong with Mr Jones?" Neurology 1988, 38:791–793.

    PubMed  CAS  Google Scholar 

  27. Caplan LR: Evidence-based medicine—concerns of a clinical neurologist. J Neurol Neurosurg Psychiatry 2001.

  28. Feinberg WM, Albers G, Barnett HJ, et al.: Guidelines for the management of transient ischemic attacks. From the Ad Hoc committee on guidelines for the management of transient ischemic attacks of the Stroke Council of the American Heart Association. Circulation 1994, 89:2950–2965.

    PubMed  CAS  Google Scholar 

  29. Albers G, Hart R, Lutsep HL, et al.: Supplement to the Guidelines for the management of Transient Ischemic Attacks. A Statement from From the Ad Hoc committee on guidelines for the management of transient ischemic attacks of the Stroke Council of the American Heart Association. Stroke 1999, 30:2502–2511.

    PubMed  CAS  Google Scholar 

  30. Albers GW, Amarenco P, Easton JD, Sacco R, Teal P: Antithrombotic and thrombolytic therapy for ischemic stroke [supplement-Sixth Consensus conference on antithrombotic therapy]. Chest 2001, 119:300S-320S.

    Article  PubMed  CAS  Google Scholar 

  31. The National Institute of Neurological Disorders and Stroke rt-PA Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581–1587.

    Article  Google Scholar 

  32. Adams HP, Brott TG, Furlan AJ, et al.: Use of thrombolytic drugs. A suppement to the guidelines for the management of patients with acute ischemic stroke. A statement for Health Care Professionals from a special writing group of the Stroke Council American Heart Association. Stroke 1996, 27:1711–1718.

    PubMed  Google Scholar 

  33. Quality Standards Subcommittee of the American Academy of Neurology, Practice advisory: Thrombolytic therapy for acute ischemic stroke—summary statement. Neurology 1996, 47:835–839.

    Google Scholar 

  34. Caplan LR: Caplan’s Stroke, a Clinical Approach, edn 3. Boston: Butterworth-Heinemann; 2000:124–130.

    Google Scholar 

  35. Caplan LR: The case against the present guidelines for stroke thrombolysis. The present recomendations for clinical use should be modified. In Thrombolytic Therapy for Stroke. Edited by Lyden PD. Tolowa, New Jersey: Humana Press; 2001:227–235.

    Google Scholar 

  36. Caplan LR, Mohr JP, Kistler JP, Koroshetz W: Thrombolysis—not a panacea for ischemic stroke. N Engl J Med 1997, 337:1309–1310, 1313.

    Article  PubMed  CAS  Google Scholar 

  37. Hacke W, Kaste M, Fieschi C, et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274:1017–1025.

    Article  PubMed  CAS  Google Scholar 

  38. Hacke W, Kaste M, Fieschi C, et al., for the Second European-Australasian Acute Stroke Study Investigators: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS-II). Lancet 1998, 352:1245–1251.

    Article  PubMed  CAS  Google Scholar 

  39. del Zoppo GJ, Higashida RT, Furlan AJ, et al.: PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998, 29:4–11.

    PubMed  Google Scholar 

  40. Furlan AJ, Higashida RT, Wechsler L, et al.: A randomized trial of intra-arterial pro-urokinase for acute ischemic stroke of less than 6 hours duration due to middle cerebral artery occlusion. PROACT Investigators. prolyse in Acute Cerebral Thromboembolism. JAMA 1999, 282:2003–2011.

    Article  PubMed  CAS  Google Scholar 

  41. Suarez J, Sunshine J, Tarr R, et al.: Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke 1999, 30:2094–2100.

    PubMed  CAS  Google Scholar 

  42. Pessin MS, del Zoppo GJ, Furlan AJ: Thrombolytic treatment in acute stroke: review and update of selective topics. In Cerebrovascular Diseases, Nineteenth Princeton Stroke Conference. Edited by Moskowitz M, Caplan LR. Boston: Butterworth-Heinemann; 1995:409–418.

    Google Scholar 

  43. Trouillas P, Brudon F, Adeleine P: Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan: a double blind study with quantified data processing. Arch Neurol 1988, 45:1217–1222.

    PubMed  CAS  Google Scholar 

  44. Cook DJ, Mulrow CD, Haynes RB: Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997, 126:376–380.

    PubMed  CAS  Google Scholar 

  45. Mulrow CD, Cook DJ, Davidoff F: Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997, 126:389–391.

    PubMed  CAS  Google Scholar 

  46. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F: Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997, 337:536–542.

    Article  PubMed  CAS  Google Scholar 

  47. Radford MJ, Foody JM: How do observational studies expand the evidence base for therapy. JAMA 2001, 286:1228–1230.

    Article  PubMed  CAS  Google Scholar 

  48. Caplan LR, Hollander J: The Effective Clinical Neurologist. Boston: Butterworth-Heinemann; 2001.

    Google Scholar 

  49. Katz JN: Patient preferences and health disparities. JAMA 2001, 286:1506–1509.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Beth Deaconess Medical Center, 330 Brookline Avenue, 02215, Boston, MA, USA

    Louis R. Caplan MD

Authors
  1. Louis R. Caplan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caplan, L.R. Is the promise of randomized control trials ("evidence-based medicine") overstated?. Curr Neurol Neurosci Rep 2, 1–8 (2002). https://doi.org/10.1007/s11910-002-0044-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-002-0044-z

Keywords

Search

Navigation